Adare and Laxxon collaborate to implement 3D printing technology in pharmaceutical manufacturing, offering advanced drug delivery options.
Adare Pharma Solutions, a global technology-driven Contract Development and Manufacturing Organization (CDMO), has entered into a collaboration with Laxxon Medical to provide the pharmaceutical market with cGMP 3D printing capabilities. This partnership will use Exentis Group’s Screen-Printed Innovative Drug (SPID) technology to 3D print oral medications with complex internal structures.
A new 3D printer and bulk mixer have been installed at Adare’s Pessano facility in Milan, Italy, where the collaboration will be based. These additions are expected to be fully operational by the end of Q4 2024, creating a flexible cGMP suite that will allow for direct scaling from laboratory quantities to clinical trial material volumes.
Adare Pharma Solutions’ CEO, Tom Sellig, talked about the partnership: “Adare’s collaboration with Laxxon expands our ability to provide incredible dose flexibility options such as taste masking, solubility enhancement, shape modifications for ease of swallowing, and multiple APIs.
The SPID Technology enables the production of complex pharmaceuticals with optimized properties, including customizable release profiles of one or more APIs, improved bioavailability, and tailored pharmacokinetics. The platform can produce multi-compartment tablets ranging from 200 microns to centimeters in diameter.
Helmut Kerschbaumer, who is the boss of Laxxon Medical, said that this partnership is very important for Laxxon. He said that Adare, with their experience in making medicines and their modern cGMP facilities, will help Laxxon make clinical samples for their partners and for their own research.
Adare’s big facility in Pessano is 220,000 square feet big and has the ability to do research and development for making new medicines quickly. They can easily move from making new medicines to making them on a large scale. The facility can make many different kinds of solid medicines, both for clinical trials and for selling to customers.
Plans are in place to install a second clinical-scale 3D production system at Adare’s Vandalia, Ohio facility by the end of Q4 2024, further expanding the reach of this innovative technology in the pharmaceutical industry.
Content source- adarepharmasolutions
Read more recent news:
- 3D Printed Glass Bricks: Building the Future, LEGO-Style
- HeyGears Unveils UltraCraft Reflex RS: Precision & Speed Redefined
- Anycubic Unveils Next-Gen Photon Mono 4 3D Printers series
- 3D Printing Reshapes Southfield’s Housing Landscape
- Amazon’s HQ2 Unveils Futuristic 3D Printed Wall That Thinks Big
Alexa Sipes is a U.S. tech journalist with 5 years of experience, now writing for 360TechInsights. She covers emerging technologies and industry trends across North America, Europe, and Asia. Sipes’ concise reporting offers readers valuable insights into the latest tech news, innovations and the companies behind them.
Feel free to reach out to me at AlexaSipes@360techinsights.com.
